BMC Cancer

1. SOLHEIM ET, Gerking Y, Krakenes T, Herdlevaer I, et al
   Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell proliferation following knockout of CDR2L.
   BMC Cancer. 2024;24:645.
   

   >> Share

   
   

   
   Br J Cancer

2. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
   The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
   Br J Cancer. 2024;130:1875-1884.
   

   >> Share

   
   

   
   Cancer Res

3. JOY JD, Malacrida B, Laforets F, Kotantaki P, et al
   Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity.
   Cancer Res. 2024 May 31. doi: 10.1158/0008-5472.CAN-23-3007.
   

   >> Share

   
   

   
   Clin Cancer Res

4. CORBAUX P, Freyer G, Glehen O, You B, et al
   Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
   Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-24-0507.
   

   >> Share

   
   

   
   Gynecol Oncol

5. CARBALLO EV, Kim KH, Penn CA
   Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
   Gynecol Oncol. 2024;187:204-211.
   

   >> Share

   
   
6. KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
   Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
   Gynecol Oncol. 2024;183:103-114.
   

   >> Share

   
   
7. PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
   Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
   Gynecol Oncol. 2024;183:61-67.
   

   >> Share

   
   
8. CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
   Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
   Gynecol Oncol. 2024;183:15-24.
   

   >> Share

   
   

   
   J Natl Cancer Inst

9. DAVIS EW, Attwood K, Prunier J, Paragh G, et al
   The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality.
   J Natl Cancer Inst. 2024 May 28:djae112. doi: 10.1093.
   

   >> Share

   
   

   
   PLoS Comput Biol

10. JITMANA K, Griffiths JI, Fereday S, DeFazio A, et al
    Mathematical modeling of the evolution of resistance and aggressiveness of high-grade serous ovarian cancer from patient CA-125 time series.
    PLoS Comput Biol. 2024;20:e1012073.
    

    >> Share

    
    

    
    PLoS One

11. REID F, Adams T, Adel RS, Andrade CE, et al
    The every woman study low- and middle-income countries edition protocol: A multi-country observational study to assess opportunities and challenges to improving survival and quality of life for women with ovarian cancer.
    PLoS One. 2024;19:e0298154.
    

    >> Share

    
    
12. PARK K, Kwon JY, Song JM, Pyeon SY, et al
    Prognostic impact of suspicious extraabdominal lymph nodes on patient survival in advanced ovarian cancer.
    PLoS One. 2024;19:e0299205.
    

    >> Share

    
    
13. HOSOKAWA S, Norimatsu Y, Shinagawa A, Kurokawa T, et al
    Assessment of the localization of chondroitin sulfate in various types of endometrial carcinoma.
    PLoS One. 2024;19:e0304420.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share